0wkin S News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Before it can actually be properly useful. i think that a follow—up - of five years for the patients included in this trial - could be informative enough to understand the - performance of the ai. within minutes of the slides being scanned, the ai will have made its assessment of the risk. in this case, it's low. but when it's at a more moderate level, the dilemma really exists. sometimes there is a grey zone and some cases are borderline, so maybe not completely good prognosis, maybe not completely bad, and in this grey zone, we need other tools to decide for the prognosis of the patient. a...

After the al's looked at the data? exactly. so here, for example, i can see that the ai risk is low. it's a low—risk patient. some cancer experts see real promise in al tools like 0wkin�*s, but there are still challenges. it's really exciting - work and it's showing where the future i lies for pathology. while it might not be absolutely there yetl for clinical deployment, - i think it's a really important first step and something that we should be encouraged by. the real benefit to patients of these is patient safety . in the first instance, _ to make sure that we don't miss cancers, that ...

Some cancer experts see real promise in al tools like 0wkin�*s, but there are still challenges. it's really exciting - work and it's showing where the future i lies for pathology. while it might not be absolutely. there yet for clinical deployment, i think it's a really important first step and something - that we should be encouraged by. the real benefit to patients of these is patient safety . in the first instance, _ to make sure that we don't miss cancers, that we can detect small. areas of cancer that could otherwise be missed by pathologists. but i think we're _ progressing along a jou...

Like 0wkin�*s, but there are still challenges. it's really exciting work, and it's showing where i the future lies for pathology. while it might not be absolutely there yetl for clinical deployment, i think it's a really - important first step _ and something that we should be encouraged by. the real benefit to patients of these is patient safety . in the first instance, _ to make sure that we don't miss cancers, that we can detect small areas of cancer that i could otherwise be - missed by pathologists. but i think we're _ progressing along a journey. and really, without - the digitisation ...

Being scanned, the ai will have made its assessment of the risk. in this case, its low, but when it's at a more moderate level, the dilemma really exists. sometimes there is a grey zone and some cases are borderline, so maybe not completely good prognosis, maybe not completely bad. and in this grey zone, we need other tools to decide for the prognosis of the patient. and here we have the information that you receive after the al's looked at the data. exactly. so, here, for example, i can see that the ai risk is low — it's a low—risk patient. some cancer experts see real promise in al tools...